ImaginAb snags GE research partnership
Biotech company ImaginAb has locked a research deal with GE Healthcare to develop PET diagnostic imaging agents for cardiovascular disease, the companies said on June 5.

Under the master research agreement, Waukesha, Wis.-based GE Healthcare will collaborate with ImaginAb to utilize the company’s antibody fragment platform to develop targeted molecular diagnostics, centered on imaging high-risk cardiovascular disease. Inglewood, Calif.-based ImaginAb is a biotechnology company that develops engineered antibody fragments for diagnostic imaging and treatment.